AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Last trade$10.97
Day change-$0.15 (-1.35%)
Day range$10.83 – $11.39
Volume1,585,814
Market cap$3.63B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.63B
Price / earnings
—
Price / book
3.42×
Price / sales
53.52×
EV / sales
51.11×
EV / EBITDA
-19.36×
Profitability
Earnings per share
-$0.45
Return on assets
-9.89%
Return on equity
-13.96%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
12.43×
Quick ratio
12.43×
Cash ratio
2.32×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$32.85M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ABCL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$10.64M
$4.05M
$8.32M
$44.85M
$8.96M
$17.08M
$4.24M
$5.05M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$10.64M
$4.05M
$8.32M
$44.85M
$8.96M
$17.08M
$4.24M
$5.05M
Selling, general and administrative
$13.61M
$13.85M
$12.33M
$17.22M
$24.96M
$21.99M
$19.07M
$19.16M
Research and development
$43.54M
$45.99M
$46.66M
$50.09M
$55.03M
$39.21M
$42.5M
$46.08M
Total operating expenses
$63.95M
$66.83M
$65.83M
$73.44M
$85.23M
$66.67M
$66.9M
$77.81M
Operating income
-$53.32M
-$62.78M
-$57.52M
-$28.58M
-$76.28M
-$49.59M
-$62.66M
-$72.76M
Interest expense
$6.87M
-$42K
$0
$0
$4.78M
$9.55M
$0
$0
Income before taxes
-$42.81M
-$58.97M
-$49.54M
-$19.5M
-$68.77M
-$36.34M
-$52.98M
-$46.83M
Income taxes
-$2.05M
-$3.54M
-$6.37M
-$10.55M
-$11.65M
-$1.62M
-$7.36M
-$12.62M
Net income
-$40.76M
-$55.43M
-$43.17M
-$8.95M
-$57.12M
-$34.73M
-$45.62M
-$34.21M
Net income attributable to common shareholders
-$40.76M
-$55.43M
-$43.17M
-$8.95M
-$57.12M
-$34.73M
-$45.62M
-$34.21M
EBITDA
-$44.66M
-$57.64M
-$50.68M
-$26.19M
-$69.18M
-$45.97M
-$57.33M
-$138.5M
Basic earnings per share
-$0.13
-$0.18
-$0.14
-$0.03
-$0.19
-$0.12
-$0.15
-$0.12
Diluted earnings per share
-$0.13
-$0.18
-$0.14
-$0.03
-$0.19
-$0.12
-$0.15
-$0.12
Recent news
Company coverage with links to the original publishers.
AbCellera Biologics reported a Q3 loss of $0.13 per share, beating consensus estimates of $0.18 loss by 27.78%. Revenue of $10.64 million surpassed estimates by 95.79%, up from $8.95 million year-over-year. The stock has gained 247.4% year-to-date. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Tarsus Pharmaceuticals reported a Q3 loss of $0.78 per share, beating consensus estimates of $1.43 loss by 45.46%. Revenue reached $194.57 million, surpassing estimates by 3.06% and up 64% year-over-year. The company has topped revenue estimates four times in the last four quarters and holds a Zacks Rank #2 (Buy) rating, though shares have underperformed the S&P 500 by 20.7% year-to-date.
Nurix Therapeutics reported Q3 2026 earnings of $4.73 per share, significantly beating the consensus estimate of a loss of $0.56 per share, with a 944.64% earnings surprise. Revenues reached $673.06 million, surpassing estimates by 383.11%. However, the stock received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions and the company's industry ranking in the bottom 33% of sectors.
The global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential.
Prelude Therapeutics reported a Q2 2025 net loss of $31.2 million, reduced operating expenses, and focused on its oral SMARCA2 degrader program while maintaining cash reserves to fund operations into Q2 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.